Okogen
Manufacturing · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
L 9/31 Queen St, Melbourne, Victoria, 30...Website
www.okogen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Okogen
Okogen is a clinical stage ophthalmic pharmaceutical company focused on innovating treatments for acute infectious conjunctivitis. Their lead product is currently in Phase 2B clinical trials, aiming to provide a comprehensive solution for both bacterial and viral forms of the condition. The company targets the growing conjunctivitis market, which is projected to reach $6.1 billion by 2031, addressing a significant gap in approved treatments for adenoviral conjunctivitis. Okogen is dedicated to enhancing lives through better vision by developing effective therapies for this widespread eye infection.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Okogen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Okogen has new funding data
Check out if Okogen is spiking on competitors!
Click to see if Okogen had a recent Job posting/layoffs
Earning: See what the market has to say on Okogen recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Okogen
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Okogen has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Okogen launches new products
Okogen, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Okogen
Find 3 more new buyers
Compare Similar Companies to Okogen
Compare insights from companies similar to Okogen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Okogen
<$5M
1-10
Private
-
2015
N/A
Company Profile Activity
Activity Insights
Okogen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Okogen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Okogen.
Okogen Tech Stack
A closer look at the technologies used by Okogen
Okogen News & Media
Okogen, Inc., Announces Ophthalmology Industry Veteran Joshua Moriarty as New Chief Executive Officer
San Diego, California and Melbourne, Australia--(Newsfile Corp. - March 8, 2022) - Okogen, an ophthalmic biotechnology company, today announced the appointment of Joshua Moriarty as the new Chief Executive Officer (CEO). Mr. Moriarty will immediately commence the role previously held by Co-Founder Brian Strem, PhD (CEO at Kiora Pharmaceuticals), who will remain with the company as a director. To view the...EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
-EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform- -EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform-Orgenesis Achieves Multiple Ranpirnase Development Milestones
FDA Pre-IND consultation completed; submission of phase 2 trial of Ranpirnase for anogenital warts on scheduleSafe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis--Phase 2 Interim Analysis Results from RUBY Clinical Trial
San Diego, California and Melbourne, Australia--(Newsfile Corp. - April 29, 2021) - Okogen, a clinical-stage specialty ophthalmic biotechnology company announced the interim analysis results from RUBY, the company's Phase 2, double-masked, placebo-controlled clinical trial evaluating the safety and efficacy of OKG-0301 in patients with acute adenoviral conjunctivitis. In 58 patients diagnosed with acute adenoviral conjunctivitis, OKG-0301 was safe and demonstrated an effective, dose-dependent an
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Okogen
Sign Up For FreeTo access detailed company insights
Okogen is a clinical stage ophthalmic pharmaceutical company focused on innovating treatments for acute infectious conjunctivitis. Their lead product is currently in Phase 2B clinical trials, aiming to provide a comprehensive solution for both bacterial and viral forms of the condition. The company targets the growing conjunctivitis market, which i... Read More
